CytRx Corporation (NASDAQ:CYTR), a biopharmaceutical research and development company specializing in oncology, announces that President and CEO Steven A. Kriegsman and Vice President of Business Development David J. Haen will present at the Rodman & Renshaw Global Investment Conference on Monday, September 9, 2013, at 10:50 a.m. Eastern time (7:50 a.m. Pacific time). The conference is being held at the Millennium Broadway Hotel in New York City.
A webcast of the presentation will be available on the Company’s website at http://cytrx.com/investors/presentations.
About the Rodman & Renshaw Global Investment Conference
The 2013 Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC, will be held in New York City from September 8 to 10, 2013 at The Millennium Broadway Hotel. More than 200 public & private companies from around the world are expected to present to an audience of over 1,500 attendees. The conference will feature tracks devoted to Biotechnology/Healthcare, Technology, Natural Resources, and Growth.About CytRx Corporation CytRx Corporation is a biopharmaceutical research and development company specializing in oncology. The CytRx oncology pipeline is focused on the clinical development of aldoxorubicin (formerly known as INNO-206), its improved version of the widely used chemotherapeutic agent doxorubicin. CytRx is conducting a global Phase 2b clinical trial with aldoxorubicin as a treatment for soft tissue sarcomas, has completed its Phase 1b/2 clinical trial primarily in the same indication and a Phase 1b study of aldoxorubicin in combination with doxorubicin in patients with advanced solid tumors, and is conducting a Phase 1b pharmacokinetics clinical trial in patients with metastatic solid tumors. The Company plans to initiate a Phase 3 global pivotal trial under a special protocol assessment (SPA) with aldoxorubicin as a therapy for patients with soft tissue sarcomas whose tumors have progressed following treatment with chemotherapy. CytRx also is initiating a Phase 2b clinical trial with aldoxorubicin in patients with late-stage glioblastoma (brain cancer). CytRx is expanding its pipeline of oncology candidates based on a novel linker platform technology that can be utilized with multiple chemotherapeutic agents and could allow for greater concentration of drug at tumor sites. The Company also has rights to two additional drug candidates, tamibarotene and bafetinib. CytRx completed its evaluation of bafetinib in the ENABLE Phase 2 clinical trial in high-risk B-cell chronic lymphocytic leukemia (B-CLL), plans to seek a partner for further development of bafetinib, and is evaluating further development of tamibarotene. For more information about CytRx Corporation, visit www.cytrx.com.